BioSpace News Archive

The board decided on October 27, 2017 to partially exercise the authorization in article 16b of the Company’s Articles of Association to issue up to 13,015,625 new shares in a private placement to a limited number of investors.

The PREVAIL data, combined with final five-year outcomes from the PROTECT-AF clinical trial, demonstrated the WATCHMAN device continues to be a safe and effective alternative to long-term warfarin therapy offering comparable stroke risk reduction for patients with non-valvular atrial fibrillation.

The company reported financial results and business updates for the quarter ended September 30, 2017.

Management will host a conference call to discuss these results and answer questions at 10:00 a.m. ET on the same day.

This was the largest ever pharmacogenomics depression trial and primarily assessed Hamilton Depression Rating Scale 17 (HAMD-17) scores from baseline to eight weeks in patients receiving GeneSight-guided therapy compared to those receiving treatment-as-usual.

“Dr. Stephan Grupp has helped to revolutionize T cell immunotherapy and we are thrilled to welcome him to TCR2’s Advisory Board,” said Mitchell Finer, PhD, Chairman of TCR2’s Advisory Board and Member of the company’s Board of Directors.

The company announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $24.00 per share, before underwriting discounts.

Spero Therapeutics, Inc.’s shares are expected to begin trading on The Nasdaq Global Select Market on November 2, 2017 under the symbol “SPRO.”

[02-November-2017] SAN DANIELE DEL FRIULI, Italy, November 2, 2017 /PRNewswire/ -- Lima Corporate announces the closing of EUR 275,000,000 aggregate principal amount of its Senior Secured Notes due 2023. The Notes bear interest at a rate of E+3.75 % per year, with a 0.00 % EURIBOR floor - a benchmark issuance among comparable companies - and are listed on the Euro MTF Ma

With perspectives from over seventeen thought leaders in the digital health space representing pharma, tech, regulatory agencies, and investors, this report, Digital Medicine 2.0, builds on the first edition, published in August 2016.